Key Takeaway
PMA-zeolite supplementation during oxaliplatin chemotherapy significantly reduced the incidence and severity of peripheral neuropathy and other side effects in a double-blind RCT.
Summary
The ZeOxaNMulti trial was a randomized, double-blind, placebo-controlled study examining whether oral PMA-zeolite (panaceo med acute) could prevent or reduce chemotherapy-induced side effects in cancer patients receiving oxaliplatin-based regimens. Oxaliplatin is well known to cause dose-limiting peripheral neuropathy alongside other gastrointestinal and hematological side effects.
Patients in the zeolite group experienced significantly lower rates and severity of peripheral neuropathy compared to the placebo group. Additional benefits were observed in reduced gastrointestinal side effects including nausea, diarrhea, and mucositis. The zeolite supplementation did not interfere with the antitumor efficacy of the chemotherapy regimen, an important safety consideration.
These findings suggest that clinoptilolite-zeolite may serve as a supportive care agent during chemotherapy by reducing toxic side effects through its adsorptive and detoxification properties. The study adds to the growing body of evidence that zeolite supplementation can improve quality of life in clinical settings involving significant toxin exposure, while maintaining a favorable safety profile.